Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients?

J Viral Hepat. 2020 Dec;27(12):1509-1510. doi: 10.1111/jvh.13369. Epub 2020 Aug 13.

Authors

Wanjia Zeng¹, Mingchen Liu¹, Siwen Peng¹, Guangxin Yu¹, Xiangwei Zhai², Xiangmei Chen¹, Fengmin Lu^{1

3}

Affiliations

¹ Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
² Department of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, China.
³ Hepatology Institute, Peking University People's Hospital, Beijing, China.

PMID: 32741086
DOI: 10.1111/jvh.13369

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Guanine / analogs & derivatives
Hepatitis B Surface Antigens*
Hepatitis B e Antigens
Hepatitis B, Chronic* / drug therapy
Humans
Kinetics
Republic of Korea

Substances

Hepatitis B Surface Antigens
Hepatitis B e Antigens
entecavir
Guanine